Daxor Co. (NASDAQ:DXR – Get Free Report) was the recipient of a large increase in short interest in the month of September. As of September 15th, there was short interest totalling 14,800 shares, an increase of 39.6% from the August 31st total of 10,600 shares. Based on an average daily volume of 4,000 shares, the short-interest ratio is currently 3.7 days. Approximately 0.7% of the shares of the company are short sold.
Daxor Stock Down 2.3 %
NASDAQ DXR traded down $0.21 on Friday, hitting $8.89. 21,291 shares of the company were exchanged, compared to its average volume of 3,723. Daxor has a 1-year low of $7.11 and a 1-year high of $10.04. The firm has a 50 day moving average of $8.90 and a two-hundred day moving average of $9.09.
Wall Street Analyst Weigh In
Separately, Ascendiant Capital Markets raised their target price on Daxor from $24.50 to $24.75 and gave the stock a “buy” rating in a research report on Monday, September 9th.
Daxor Company Profile
Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions.
See Also
- Five stocks we like better than Daxor
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- Simon Property REIT: A Safe Bet for Growth and Steady Dividends
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- CarMax’s Impressive Rally: What Investors Should Watch Next
- What is the Shanghai Stock Exchange Composite Index?
- MarketBeat Week in Review – 9/23 – 9/27
Receive News & Ratings for Daxor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Daxor and related companies with MarketBeat.com's FREE daily email newsletter.
